Seward Stomacher used for Hygiene Monitoring and Biosecurity
Seward Ltd, manufacturers of the world leading range of Stomacher paddle blenders and Stomacher accessories used in sample preparation for microbiological analyses, have highlighted the highly effective use of its Stomacher technology in combination with sponge swabs for hygiene monitoring and biosecurity applications.
Hygiene monitoring in food and pharmaceutical production facilities and clinical environments requires simple sampling techniques with excellent microbial recovery rates across a spectrum of different species. A recent study [1] has confirmed the effectiveness of the combined sponge swab and Stomacher sampling methodology for sampling a large surface area.
This popular sampling method utilises sponge swabs pre-dosed with buffer to swab a surface and then, to recover the micro flora, the sponge swabs are processed in the Stomacher 400 Circulator. A number of suppliers offer pre-manufactured devices such as 3M and Technical Services Consultants Ltd, which work very effectively in Stomacher products. Various different approaches can be applied, processing either pooled samples in the Stomacher® 400 or individual swabs in the Stomacher 80 Biomaster.
Due to the efficacy of the Stomacher and sponge swab combination, it has also been adopted in more critical fields such as biosecurity. Security services on both sides of the Atlantic have recently adopted the technique to detect and monitor the potential spread of weaponised bacterial contaminates such as Bacillus anthracis.
The effectiveness of the sponge and Stomacher technique over the swab technique for sample collection is demonstrated in a recent paper [1] concerning the clinical environment and the monitoring of Acinetobacter baumannii. The sponge and Stomacher technique allows for a greater surface area to be tested than achievable with a swab head. This also means that the sponge method delivers greater sensitivity.
Reference
1. K.A. Thom, et al., Comparison of swab and sponge methodologies for identification of Acinetobacter baumannii from the hospital environment. Journal of Clinical Microbiology 2012, 50(6):2140.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance